Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution

Mesenchymal Stem Cell Exosome Treatment of Congenital Myasthenic Syndrome

Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.

Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.

Inclusion Criteria:

• Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician.
• Patients must be able to provide informed consent, or have a guardian who does.
• Patient must be able to travel to the site of treatment.

Exclusion Criteria:

• Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.